|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
RED CELLS
From the Departments of Pediatrics and Medicine, San
Francisco General Hospital, Departments of Pediatrics, Medicine and
Anatomy, University of California, San Francisco, Center for Biomedical
Laboratory Sciences, San Francisco State University, and the Northern
California Comprehensive Sickle Cell Center, San Francisco; and
Glycobiology Research and Training Center, University of California,
San Diego, La Jolla.
The adherence of sickle red blood cells (RBCs) to the vascular
endothelium may contribute to painful vaso-occlusion in sickle cell
disease. Sickle cell adherence involves several receptor-mediated processes and may be potentiated by the up-regulated expression of
adhesion molecules on activated endothelial cells. Recent results showed that thrombin rapidly increases the adhesivity of endothelial cells for sickle erythrocytes. The current report presents the first
evidence for the novel adhesion of normal and, to a greater extent,
sickle RBCs to endothelial P-selectin. Studies of the possible
interaction of erythrocytes with P-selectin revealed that either
P-selectin blocking monoclonal antibodies or sialyl Lewis
tetrasaccharide inhibits the enhanced adherence of normal and sickle
cells to thrombin-treated endothelial cells. Both RBC types also adhere
to immobilized recombinant P-selectin. Pretreating erythrocytes with
sialidase reduces their adherence to activated endothelial cells and to
immobilized recombinant P-selectin. Herein the first evidence is
presented for the binding of normal or sickle erythrocytes to
P-selectin. This novel finding suggests that P-selectin inhibition be
considered as a potential approach to therapy for the treatment of
painful vaso-occlusion in sickle cell disease.
(Blood. 2001;98:1955-1962) The interaction of P-selectin and its ligands
contributes to the specificity of interactions among endothelial cells,
platelets, and leukocytes during inflammation, coagulation, and
atherosclerosis.1-8 The expression of P-selectin on
endothelial cells and platelets requires activation of these cells by
specific biologic response modifiers, such as thrombin, which has the
capacity in both cell types to trigger rapid translocation of
P-selectin from intracellular storage granules to the membrane surface
and in endothelial cells to induce also slower transcriptional
up-regulation of the P-selectin gene.9-11 Another requisite for
P-selectin-mediated adhesive interactions is a P-selectin ligand whose
specificity is conferred by the particular transferases that generate
its unique carbohydrate composition.1,4,6-8,12,13 Erythrocytes are not considered to participate in these
receptor-mediated processes,8 because normal red blood
cells (RBCs) are not known to bear selectin ligands or to bind to
P-selectin.14
The conventional view that erythrocyte sickling in small blood vessels
causes the painful vaso-occlusion of sickle cell disease does not
explain why only 5% of patients account for 30% of pain crises in
this common debilitating genetic condition.15,16 An
emerging hypothesis is that vaso-occlusion involves factors besides
erythrocyte sickling. The adherence of sickle cells to vascular
endothelium may be particularly important to
vaso-occlusion.17 Hebbel and colleagues found that sickle
erythrocytes are abnormally adherent to endothelial cells in
vitro18 and that the adhesivity of sickle RBCs in vitro
correlates with vaso-occlusive severity.19 Kaul and
associates determined that endothelial adherence of human sickle cells
infused into the rat microcirculation has the remarkable capacity to
initiate vaso-occlusion ex vivo.20 Adhesion pathways implicated in sickle cell disease involve several specific interactions among the sickle cell molecules Endothelial adhesivity is enhanced by the additional adhesion molecules
expressed when endothelial cells are activated.24 Several
biologic modifiers of endothelial cell adhesivity are operative in
sickle cell disease, including thrombin,25,26 platelet-activating factor (PAF),27
histamine,28 tumor necrosis factor- The importance of endothelial cell activation to sickle cell
vaso-occlusion is demonstrated by recent findings regarding the effects
of PAF and thrombin, 2 endothelial cell agonists found at increased
levels in sickle cell disease.25,27 The discovery that
blocking Blood samples
Thrombin treatment of endothelial monolayers, static gravity
adherence with dip rinse, and adherence inhibition assays
Because of potential modulatory effects of heparin on adherence, we used the static adherence assay to compare the adhesivity of sickle cells and autologous plasma according to whether they were prepared with citrate anticoagulant or with heparin. We detected no significant difference in these 2 anticoagulants. The contribution of P-selectin to thrombin-enhanced adherence was determined by comparing the effects on adherence of exposing HUVECs to no antibody, a 1:200 dilution of nonblocking P-selectin monoclonal antibodies (mAbs) AC1.2 (BD Pharmingen, San Diego, CA), or a 1:200 dilution of blocking P-selectin mAb 9E1 (R & D Systems, Minneapolis, MN). The contribution of P-selectin to thrombin-enhanced adherence was confirmed by comparing the effects on adherence of adding to each well medium alone, 100 µM sialyl Lewis X (sLeX) tetrasaccharide (sLeX, Sigma), or 500 µM 3'-sialyl-lactose (sLac, Glycotech, Rockville, MD), an analogous sugar that does not bind P-selectin. Flow cytometry We used as primary antibodies for indirect immunofluorescence staining of erythrocytes in flow cytometry the mAbs AC1.2 and 9E1, which are specific for P-selectin. For each mAb we used an isotype-matched nonspecific mAb or the secondary antibody alone as negative controls. The secondary antibody was goat anti-mouse or goat anti-rat IgG conjugated to biotin (Sigma), which was reacted with fluorescein-conjugated Neutravidin (Molecular Probes, Eugene, OR). Fluorescence intensity of 20 000 cells/experiment was quantified on a FACS-scan flow cytometry system and analyzed using Cell-Quest software (Becton Dickinson, San Jose, CA).Nonstatic adherence to immobilized sialic acid-binding lectin-Ig chimeras or P-selectin-Ig chimeras using a rotatory adherence assay We immobilized on microtiter wells 400 ng bovine serum albumin (BSA; Sigma), a sialic acid-binding lectin (Siglec)-6-Ig chimera, mutated Siglec-7-Ig chimera, or P-selectin-Ig chimera.47-49 Siglec-6 is a sialic acid-binding lectin of the immunoglobulin superfamily that does not bind P-selectin ligands or erythrocytes, which we used as negative controls. Whereas Siglec-7 does bind RBCs, the mutated Siglec-7 we used as a negative control does not.49 These chimeras were applied to the wells in 10 mM carbonate buffer overnight and then blocked with 0.5% BSA in Hanks buffered salt solution (University of California, San Francisco, Cell Culture Facility) before incubation with RBCs using a published rotatory adhesion assay.50 Erythrocyte adherence to BSA, Siglec-6, mutant Siglec-7, or P-selectin was measured as the number of RBCs observed in 8 random 0.04-mm2 fields for each condition. The adherence data are presented as percent adherence where 100% is the mean number of untreated nonsickle erythrocytes/field in a well in which BSA or Siglec was immobilized.Enzyme treatment of test RBCs To determine whether sialic acid on erythrocytes is a recognition determinant for P-selectin, prior to testing RBC adherence we treated the erythrocytes with sialidase using a published method.51 Packed RBCs were mixed with an equal volume of buffer or 0.1 U/mL Vibrio cholerae sialidase (Calbiochem, San Diego). No hemolysis was detected with 0.1 U/mL sialidase as assayed by colorimetric spectrophotometry. Efficacy of sialidase on RBCs was confirmed by agglutination with peanut extract lectin (Arachis hypogea lectin, Sigma).Statistical analyses For each experiment mean adherence was set arbitrarily at 100% for the control data. The mean adherence of data derived from perturbations of control conditions were calculated as a percentage relative to the control. We then calculated the average of the means from replicate experiments. The uncertainty of the estimate of the means from the data distributed in each set is described as SEM. An SEM of 0% resulted when control data sets were normalized to 100%. The number of replications for each study is stated in the figure legends. We used the paired one-tailed Student t test to compare changes in adhesion resulting from different perturbations of the system.52
Effect of P-selectin mAb on erythrocyte adherence to endothelial cells We assessed the effects of the P-selectin blocking mAb 9E1 on the static adherence of nonsickle or sickle RBCs to untreated or thrombin-treated HUVEC monolayers.46 The data shown in Figure 1A are consistent with previous reports that the adherence of sickle cells to untreated endothelial cells is greater than that of nonsickle RBCs18,46 and that the adherence of both RBC types to thrombin-treated endothelium is increased compared to untreated endothelium.46 Figure 1A also shows that blocking endothelial monolayers with mAb 9E1 reduced the adherence of nonsickle RBCs by 21% to untreated endothelium (100% ± 0% to 79% ± 11%; P = .046) and 51% to thrombin-treated endothelium (266% ± 72% to 131% ± 34%; P = .006). Blocking with mAb 9E1 reduced the adherence of sickle cells by 30% to untreated endothelium (132% ± 0% to 93% ± 11%; P = .002) and by 76% to thrombin-treated endothelium (490% ± 188% to 119% ± 18%; P = .038). These reductions in adherence were statistically significant but partial. The persistence of a portion of adhesivity after blocking P-selectin reveals that other adhesion mechanisms also are involved.
Further evidence for the involvement of other pathways was derived from a single titration experiment in which we tested the effect of 1:2000, 1:200, and 1:20 dilutions of mAb 9E1 on erythrocyte adherence to thrombin-activated HUVECs (Figure 1B). We determined that the adherence of nonsickle and sickle RBCs was reduced, respectively, 64% and 70% by a 1:2000 dilution of the mAb, 72% and 84% by a 1:200 dilution, and 66% and 83% by a 1:20 dilution. The persistence of similar levels of adherence at our standard 1:200 mAb dilution and at a 10-fold higher titer of 1:20 further supports the involvement of other adhesion pathways. To verify the specificity of P-selectin blocking, in 3 replicate experiments we compared the effects of a pair of isotype-matched P-selectin mAbs, the blocking mAb 9E1 and the nonblocking mAb AC1.2, on RBC adhesion to thrombin-treated endothelial cell monolayers (data not shown). Treatment with AC1.2 resulted in no significant reduction in the adherence of either nonsickle (148% ± 25% to 160% ± 6%; P = .227) or sickle (318% ± 29% to 359% ± 25%; P = .242) RBCs from that observed without mAb. Compared to the adherence observed with AC1.2, treatment of endothelial cells with 9E1 reduced adherence by 48% for nonsickle cells (160% ± 6% to 84% ± 23%; P = .005) and 58% for sickle cells (359% ± 25% to 150% ± 38%; P = .039). Although the exact number of adherent erythrocytes and fractional inhibition varied among different experiments, different patients, patient status, and preparations of HUVECs, we consistently found statistically significant adhesion of both nonsickle and sickle RBCs to endothelial P-selectin. These data taken together provide evidence for the novel adherence of normal and, to a greater degree, sickle erythrocytes to P-selectin on activated endothelial cells. They also support the contribution of P-selectin-independent pathways in thrombin-enhanced adherence. Effect of sLeX tetrasaccharide on erythrocyte adherence to endothelial cells The sLeX antigen is a recognition determinant for selectins that selectively inhibits their adhesivity; sLac is a saccharide that is structurally related to sLeX but does not bind to P-selectin.1,4,6-8,13 In 4 replicate experiments we compared the static adherence of RBCs to endothelial cells in the absence of either saccharide, the presence of sLac, and the presence of sLeX. As shown in Figure 2, adherence to untreated endothelial cells with no added saccharide was not reduced significantly by the addition of sLac for either nonsickle (100% ± 0% to 105% ± 15%; P = .373) or sickle cells (143% ± 0% to 144% ± 44%; P = .493). Neither did sLac reduce significantly the adherence to thrombin-treated endothelial cells for either nonsickle (145% ± 31% to 162% ± 28%; P = .207) or sickle cells (325% ± 73% to 304% ± 74%; P = .240). The inhibitory effect of sLex on adherence was not significant with untreated endothelial cells but significant with thrombin-treated cells. Although not significant, compared with the adherence to untreated endothelial cells with sLac present, the addition of sLeX reduced adherence by an estimated 48% for nonsickle (105% ± 15% to 55% ± 12%; P = .063) and 37% for sickle cells (144% ± 44% to 91 ± 8%; P = .121). Compared with the adherence to thrombin-treated endothelial cells when sLac is present, adherence was reduced significantly by the addition of sLeX by 49% for nonsickle (162% ± 28% to 82% ± 41%; P = .047) and 36% for sickle cells (304% ± 74% 196% ± 38%; P = .037). These findings are consistent with the adhesion of nonsickle and sickle erythrocytes to P-selectin on activated endothelial cells. The incomplete inhibition observed with sLeX is not surprising because the inhibitory potency of this saccharide for P-selectin, while specific, is not strong.7 The absence of an inhibitory effect by sLac confirms the specificity of sLeX for P-selectin in the static adhesion assay.
Although it is reasonable to conclude that the P-selectin mAb 9E1 and sLeX affect the same molecular interaction,7 we directly tested this precept in our system. We performed an experiment in which we compared the effects of these inhibitors singly and in combination. RBC adherence to thrombin-treated endothelial cells was inhibited nearly identically by mAb 9E1, sLeX, and their combination for nonsickle cells (17%-22%) and for sickle cells (43%-47%). The lack of additive effect is consistent with the knowledge that sLeX and the P-selectin participate in the same molecular interaction.7 Because neither inhibitor nor their combination completely abrogated adherence, these results too are consistent with the existence of a P-selectin independent pathway for adhesion to thrombin-treated endothelial cells. In our studies of mAb 9E1 only endothelial cells were exposed to the blocking agent, but in these studies of sLeX both endothelial and RBCs were exposed to the inhibitor. To assess whether the P-selectin blocked by sLeX may also have been on RBCs, we performed a flow cytometry study of nonsickle and sickle RBCs using P-selectin mAbs AC1.2 and 9E1. We detected no signal indicative of the presence of P-selectin on either type of erythrocyte (data not shown), which is consistent with prior reports of the absence of P-selectin from erythroid cells.53 Adherence of erythrocytes to immobilized recombinant P-selectin Multiple molecular mechanisms have been described for sickle cell adherence to unperturbed and activated endothelium. Our results from these studies on thrombin-activated HUVECs also may reflect the participation of adhesion molecules besides P-selectin, such as 1- and 3-integrins dissociated from their
matrix binding sites (our unpublished data, 2001), and unmasked
matrix proteins.54 As with leukocyte-endothelial
interactions, the actual binding we observe may involve other molecules
as well. Yet, selectin interactions typically initiate such adhesion
cascades and are critically required. To directly confirm the role of
P-selectin in sickle cell adhesion, we tested the nonstatic adhesion of
RBCs to a recombinant P-selectin-Ig chimera47 immobilized
on plastic microtiter wells using a rotatory adherence
assay.50 The data shown in Figure
3 demonstrate our comparison of the
adherence of RBCs to P-selectin, to BSA, or to nonbinding Siglec-6 or
mutated Siglec-7 chimeras, which share the Ig-Fc domain with the
P-selectin construct.48,49 The adherence of nonsickle
cells to P-selectin is a significant 46% greater than to BSA
(146% ± 16% compared to 100% ± 0%; P = .031) and
a nearly significant 41% greater than to Siglec-6 or mutated Siglec-7
(146% ± 16% compared to 104% ± 9%; P = .056).
The adherence of sickle cells to P-selectin is 72% greater than to BSA
(259% ± 44% compared to 151% ± 0%; P = .030) and
74% greater than to Siglec-6 or mutated Siglec-7 (259% ± 44%
compared to 149% ± 7%; P = .017). The presence of 5 mM EDTA reduced the adherence to P-selectin by 35% for nonsickle cells (146% ± 16% to 95% ± 11%; P = .027) and 32% for
sickle cells (259% ± 44% to 177% ± 18%;
P = .016). These statistically significant and near
significant differences provide further evidence that normal and, to a
larger measure, sickle erythrocytes adhere to P-selectin. The
statistically significant reduction of binding resulting from chelating
calcium with EDTA confirms the specificity of P-selectin binding.
Regarding the EDTA-resistant binding to P-selectin, we previously have
established that P-selectin has 2 binding components, one EDTA
sensitive and a second that is only sensitive to high (20 mM)
concentrations of EDTA.47 The second component, which is
not inhibited by the calcium chelating effect of EDTA but by its
polycarboxylic acid nature, may represent the second anion binding site
postulated for P- and L-selectin.
Effect of erythrocyte sialidase treatment on their adherence to endothelium and to immobilized P-selectin The above findings indicate that normal erythrocytes have a ligand for P-selectin, which is enhanced markedly on sickle cells. The only published precedent for P-selectin binding activity on mature RBCs is on malarial parasitized cells, but the origin and nature of that ligand was incompletely characterized and appears to be malarial in origin.55,56 Ligand activity for P-selectin is typically mediated by sialylated, fucosylated, sulfated recognition determinants of membrane glycoproteins and glycolipids.6,8To assess the importance of erythrocyte membrane sialic acid as a
binding determinant for P-selectin, we treated RBCs with sialidase
before assaying their static adherence to endothelial monolayers, as
has been described.50 Figure
4A demonstrates that sialidase treatment
of erythrocytes reduced adherence to untreated HUVECs by 47% for
nonsickle cells (100% ± 0% to 53% ± 13%;
P = .018) and by 36% for sickle cells (297% ± 0% to
191% ± 67%; P = .106), Sialidase treatment of RBCs
significantly reduced adherence to thrombin-treated HUVECs by 81% for
nonsickle (360% ± 125% to 68% ± 15%; P = .047)
and 63% for sickle cells (766% ± 168% to 282% ± 133%;
P = .044). These data provide a partial characterization
of a novel erythrocyte P-selectin ligand that uses sialic acid as a
recognition determinant.
To further explore the importance of sialic acid to the erythrocyte-binding determinant for P-selectin we treated RBCs with sialidase50 before assaying their nonstatic adherence to P-selectin and to control Siglec-6. The results shown in Figure 4B demonstrate that treatment of nonsickle cells with sialidase has no significant effect on their adherence to Siglec-6 (110% ± 11% to 79% ± 13%; P = .089) or to P-selectin (134% ± 14% to 88% ± 11%; P = .066). Treatment of sickle cells with sialidase also had no significant effect on their adherence to Siglec-6 (179% ± 7% to 157% ± 18%; P = .089) but a significant 33% reduction in their adherence to P-selectin (273% ± 28% to 182% ± 17%; P = .004). The finding that sialidase causes a statistically significant reduction in the adherence of sickle cells to P-selectin is consistent with the sialidase effects on sickle cell binding to thrombin-treated HUVECs described above. These results further support the partial characterization of a sickle cell P-selectin ligand, which uses sialic acid as a recognition determinant. To confirm in our system the canonical requirement of sialic acid for P-selectin binding,7,50 we compared the effects of treating erythrocytes with sialidase and endothelial cells with mAb 9E1 singly and in combination. We observed that adherence to thrombin-treated endothelial cells was inhibited to a similar degree by sialidase, mAb 9E1, and their combination for nonsickle (17%-24%) and for sickle cells (29%-38%). The lack of additive effect is consistent with the participation of sialic acid and P-selectin in the same molecular interaction and with the adhesion of erythrocytes to P-selectin requiring a sialidase recognition determinant. Still, the existence of a sialidase-sensitive pathway not involving P-selectin cannot be excluded.
Taken together, our data indicate a novel mechanism for sickle cell adherence to thrombin-treated endothelial cells via P-selectin. The partially characterized P-selectin ligand contains sialic acid and is the first reported selectin ligand activity on circulating erythrocytes that are not infected by malaria. The potential importance of P-selectin in sickle cell vaso-occlusion was implicit in the suggestion that sickle cell adhesion may resemble the process of leukocyte adherence.22 Erythrocyte adhesion to P-selectin also suggests possible molecular mechanisms for the adherence of activated platelets to sickle cells,57 cooperative heterocellular interactions in sickle cell vaso-occlusion,57-60 and the retention of erythrocytes in red thrombi.61,62 The modest adherence that we noted of nonsickle cells to P-selectin does not diminish the importance of sickle cell adherence. Indeed, our finding is consistent with previous reports of a lesser degree of nonsickle RBC adherence to endothelial cells.18,46 We believe the binding of sickle cells is much more robust than that of nonsickle cells because multiple adhesion systems are involved.22 The binding of nonsickle cells is weaker and therefore more susceptible to variation in relation to the background "noise" in adherence. When all of our data are taken together, particularly those shown in Figure 1A, there is evidence for lower level but significant P-selectin-mediated binding of nonsickle cells. The adherence of nonsickle erythrocytes may have little impact on blood flow in a physiologic setting, where normally deformable RBCs easily maneuver past a potential nidus of occlusion. However, 3 important differences distinguish the pathophysiologic setting of sickle cell disease from normal. First, the likely activated condition of endothelial cells in sickle cell disease40-43 results in the expression of additional adhesion molecules that presumably strengthen low affinity P-selectin-mediated adherence. Second, the delay in microvascular transit time imposed on circulating sickle cells by the adherent nidus of highly adhesive cells promotes deoxygenation and polymerization of hemoglobin S to generate poorly deformable, reversibly sickled cells.63 Third, these reversibly sickled cells and the inherently poorly deformable, irreversibly sickled cells reach an impasse behind the adherent nidus to complete the vaso-occlusive process.20 These conditions that contribute to vaso-occlusion in sickle cell disease are not extant in the normal circulation. In our studies, P-selectin had significant effects both on static adhesion against the force of gravity orthogonal to the cell surface and on nonstatic adhesion against the tangential shear forces in a rotatory adhesion assay. Hebbel has elucidated the potential enunciated importance of both static and flow adherence studies to sickle cell vaso-occlusion.22 Based on the flow adhesion models of Springer and coworkers for leukocytes64-66 and of Ho and colleagues for Plasmodium falciparum-infected erythrocytes,55,56 in which tethering and rolling adhesion is mediated by P-selectin and firm adherence is effected by higher affinity adhesion molecules, it is tempting to predict a greater role for P-selectin in flow than in static adherence. Current experiments in our laboratory are comparing the effects of P-selectin in assays of the flow and static adherence in vitro and being tested in vivo using our sickle cell mouse model.67,68 Our finding of only partial inhibition of sickle and normal erythrocytes adherence to thrombin-activated HUVECs using blocking P-selectin mAbs with or without sLeX indicates the presence of P-selectin-independent mechanisms of activated adhesion. This is further supported by the partial inhibition of erythrocyte adherence to recombinant P-selectin in the presence of EDTA or with prior sialidase treatment of the RBCs. Possible alternative mechanisms of sickle cell adhesion to thrombin-activated endothelial cells include adherence to the redistributed endothelial integrins (our unpublished data, 2001) or exposed matrix proteins,54 the use of the putative second ligand binding site of endothelial P-selectin,47 and the adhesion of endothelial P-selectin to sulfatide in erythrocyte membranes.69-72 These sulfated glycolipids have ligand activity for P-selectin70 and bind the matrix proteins vWF, laminin, and TSP.73 The sulfated lipid purified by Hillery and colleagues from sickle cell membranes binds TSP and laminin, is resistant to sialidase treatment,74 and may comprise the sialidase-resistant component of erythrocyte P-selectin ligand activity that we identified. Identifying these additional possible pathways for P-selectin-mediated sickle cell adherence may provide important insights into sickle cell adherence and added guidance for the development of new therapy for sickle cell vaso-occlusion. Detailed understandings of hemoglobin S polymerization notwithstanding, the factors that initiate painful vaso-occlusion in sickle cell disease have not been identified.17 In this regard, the novel adhesion mechanism we have discovered involves 2 temporal variations with the potential to influence adhesion and occlusion. The expression of P-selectin on endothelial cell surfaces in response to conditions active in sickle cell disease suggests a possible role for such variations in endothelial adhesivity as a determinant of painful vaso-occlusion. Another possible influence on the seemingly random vaso-occlusive events of sickle cell disease could stem from fluctuations in the presentation of P-selectin ligand on sickle RBCs. Our characterization of this ligand is incomplete. We have demonstrated that, as with other P-selectin ligands,7,50 sialic acid is an important recognition determinant. The primary ligand for P-selectin is P-selectin glycoprotein ligand-1 (PSGL-1),7 and the precise molecular interactions between P-selectin and this counterreceptor and with the recognition determinant sLeX have recently been solved.75 These interactions are germane to our preliminary attempts at defining the ligand. In pilot studies we found no evidence of PSGL-1 on sickle RBCs using mAb 2PH1, which is specific for PSGL-1, or KPL1, which is specific for tyrosine sulfated PSGL-1 (both from BD Pharmingen) in flow cytometry (data not shown). We did, however, detect a flow cytometry signal from a fraction of sickle cells using the sLeX mAb HECA-452 (BD Pharmingen; data not shown).6 The intensity of this sLeX signal varied among patients and over time. The nature of the sickle cell ligand for P-selectin is currently under further investigation in our laboratory. Our preliminary evidence for the presence of sLeX on sickle cell membranes suggests a second possible temporal determinant derived from P-selectin-dependent adhesion. For instance, Lewis RBC antigens are not synthesized by erythrocytes, but consist of glycolipids incorporated into erythrocyte membranes from the plasma into which they are secreted by intestinal epithelial cells.76 It is tempting to speculate that fluctuations in the synthesis, constitution, plasma concentrations, and membrane incorporation of sLeX and other P-selectin recognition determinants may influence the acquisition of P-selectin ligands by circulating erythrocytes. Such variations could contribute to the variability in sickle cell adhesivity and occurrence of pain. Alternatively, P-selectin ligand on sickle cells, as with certain other adhesion molecules on RBC membranes, may be residual from less mature stages of erythroid development,77,78 in which case fluctuations in rates of reticulocytosis may contribute to variations in the adhesivity of sickle cells and the occurrence of pain. We found in pilot flow cytometry experiments that recombinant P-selectin binds only to subpopulations of sickle and nonsickle erythrocytes (data not shown), a binding pattern consistent with either of these 2 mechanisms of ligand presentation. The complexity of sickle cell adhesion mechanisms will most certainly deepen as the molecular nature of these interactions is defined. For instance, in our preliminary attempts to define the P-selectin ligand we have pretreated erythrocytes with 0.02% trypsin. This reduced substantially the adherence of sickle and nonsickle cells to untreated and thrombin-treated endothelial cells but did not reduce significantly their adhesion to immobilized P-selectin (data not shown). These results suggest that the erythroid P-selectin ligand is probably not a glycoprotein, but that proteolysis of erythrocyte membranes reduces RBC adherence to endothelial cell adhesion molecules other than P-selectin. These preliminary results and the full characterization of this P-selectin ligand are currently being pursued in our laboratory. It will be useful to correlate levels of adhesivity with independent markers of cell age, such as cell density or RNA content, as an indication of whether the ligand is acquired from the plasma by circulating sickle cells or residual from RBC precursors. Our results suggest that P-selectin be considered as a candidate molecule for new therapeutic approaches for the painful vaso-occlusion of sickle cell disease. Potential new therapeutic strategies include the use of antagonists of endothelial cell activation79 and inhibitors of P-selectin-ligand interactions,80 the latter of which includes heparin.47,74,81,82 The published suggestion that heparin therapy may be efficacious in reducing the frequency of sickle cell pain crises83 could be verified presently, because there is much clinical experience using heparin for other vaso-occlusive diseases.
We wish to thank Dr Charles McCulloch for statistical advice; Drs Vishwanath Lingappa, Marion Reid, and Steven Spitalnik for helpful discussions; Dr Reid for the gift of peanut agglutinin; and especially our patients whose cooperation, support, and trust made this work possible.
Submitted August 29, 2000; accepted May 21, 2001.
Supported in part by a Sickle Cell Scholar's Award from the National Institutes of Health (to N.M.) and grants from the National Institutes of Health (to S.R., A.V., and S.E.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Stephen H. Embury, Bldg 100, Rm 263, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110; e-mail: sembury{at}itsa.ucsf.edu.
1. Rosen SD, Bertozzi CR. The selectins and their ligands. Curr Opin Cell Biol. 1994;6:663-673[CrossRef][Medline] [Order article via Infotrieve]. 2. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314[CrossRef][Medline] [Order article via Infotrieve].
3.
McEver RP, Moore KL, Cummings RD.
Leukocyte trafficking mediated by selectin-carbohydrate interactions.
J Biol Chem.
1995;270:11025-11028 4. Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost. 1995;74:224-227[Medline] [Order article via Infotrieve]. 5. Rosen SD, Bertozzi CR. Two selectins converge on sulphate. Leukocyte adhesion. Curr Biol. 1996;6:261-264[CrossRef][Medline] [Order article via Infotrieve].
6.
Kansas GS.
Selectins and their ligands: current concepts and controversies.
Blood.
1996;88:3259-3287 7. Varki A. Selectin ligands: will the real ones please stand up? J Clin Invest. 1997;99:158-162[Medline] [Order article via Infotrieve]. 8. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1999:1.
9.
Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF.
A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation.
J Cell Biol.
1985;101:880-886
10.
McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF.
GMP-140 a platelet
11.
Barkalow FJ, Goodman MJ, Gerritsen ME, Mayadas TN.
Brain endothelium lack one of two pathways of P-selectin-mediated neutrophil adhesion.
Blood.
1996;88:4585-4593 12. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997;100:S97-103. 13. Wagers AJ, Stoolman LM, Kannagi R, Craig R, Kansas GS. Expression of leukocyte fucosyltransferases regulates binding to E-selectin: relationship to previously implicated carbohydrate epitopes. J Immunol. 1997;159:1917-1929[Abstract]. 14. Telen MJ. Red blood cell surface adhesion molecules: their possible roles in normal human physiology and disease. Semin Hematol. 2000;37:130-142[CrossRef][Medline] [Order article via Infotrieve]. 15. Ferrone FA, Cho MR, Bishop MF. Can a successful mechanism for HbS gelation predict sickle cell crisis? In: Beuzard Y,Charache S,Galacteros F, eds. Approaches to the Therapy of Sickle Cell Anemia. Paris: Les Editions Inserm; 1985:53-66. 16. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med. 1991;325:11-16[Abstract]. 17. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Pathogenesis of vasoocclusion. In: Embury SH,Hebbel RP,Mohandas N,Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994:311-326. 18. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium. Possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980;65:154-160. 19. Hebbel RP, Boogaerts MAB, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia. N Engl J Med. 1980;302:992-995[Abstract].
20.
Kaul DK, Fabry ME, Nagel RL.
Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications.
Proc Natl Acad Sci U S A.
1989;86:3356-3360 21. Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol. 1996;3:118-124[Medline] [Order article via Infotrieve]. 22. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997;99:2561-2564[Medline] [Order article via Infotrieve].
23.
Harlan JM.
Introduction: anti-adhesion therapy in sickle cell disease.
Blood.
2000;95:365-367 24. Silverstein RL. The vascular endothelium. In: Gallin JI,Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. Philadelphia: Lippincott Williams & Wilkins; 1999:207-225. 25. Francis RB. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19:105-111[Medline] [Order article via Infotrieve]. 26. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost. 1994;71:169-172[Medline] [Order article via Infotrieve]. 27. Oh SO, Ibe BO, Johnson C, Kurantsin-Mills J, Raj JU. Platelet-activating factor in plasma of patients with sickle cell disease in steady state. J Lab Clin Med. 1997;130:191-196[CrossRef][Medline] [Order article via Infotrieve]. 28. Enwonwu CO, Lu M. Elevated plasma histamine in sickle cell anaemia. Clin Chim Acta. 1991;203:363-38[CrossRef][Medline] [Order article via Infotrieve]. 29. Francis RB Jr, Haywood HJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc. 1992;84:611-615[Medline] [Order article via Infotrieve]. 30. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br J Haematol. 1994;87:592-597[Medline] [Order article via Infotrieve]. 31. Taylor SC, Shacks SJ, Qu Z. In vivo production of type 1 cytokines in healthy sickle cell disease patients. J Natl Med Assoc. 1999;91:619-24[Medline] [Order article via Infotrieve].
32.
Sherwood JB, Goldwasser E, Chilcote R, Carmichael LD, Nagel RL.
Sickle cell anemia patients have low erythropoietin levels for their degree of anemia.
Blood.
1986;67:46-48
33.
Solovey A, Gui L, Ramakrishnan S, Steinberg MH, Hebbel RP.
Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells.
Blood.
1999;93:3824-3830
34.
Setty BN, Stuart MJ.
Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease.
Blood.
1996;88:2311-2320 35. Inwald DP, Kirkham FJ, Peters MJ, et al. Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol. 2000;111:474-481[CrossRef][Medline] [Order article via Infotrieve]. 36. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-420[Medline] [Order article via Infotrieve]. 37. Rank BH, Carlsson J, Hebbel RP. Abnormal redox status of membrane-protein thiols in sickle erythrocytes. J Clin Invest. 1985;75:1531-1537. 38. Hebbel RP, Visser MR, Goodman JL, Jacob HS, Vercellotti GM. Potentiated adherence of sickle erythrocytes to endothelium infected by virus. J Clin Invest. 1987;80:1503-1506.
39.
Shiu YT, Udden MM, McIntire LV.
Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells.
Blood.
2000;95:3232-3241 40. Nadeau K, Gee B, Jennette JC, Tilney N, Trudel M, Platt OS. Increased inflammatory and endothelial cell factors in tissues from humans and mice with sickle cell disease [abstract]. Blood. 1997;90(suppl 1):125A. 41. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 1996;81:96-98[CrossRef][Medline] [Order article via Infotrieve].
42.
Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP.
Circulating activated endothelial cells in sickle cell anemia.
N Engl J Med.
1997;337:1584-1589 43. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998;101:1899-1904[Medline] [Order article via Infotrieve].
44.
Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS.
Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor.
Blood.
2000;95:368-374
45.
Hebbel RP.
Clinical implications of basic research: blockade of adhesion of sickle cells to endothelium by monoclonal antibodies.
N Engl J Med.
2000;342:1910-1912
46.
Manodori AB, Matsui NM, Chen JY, Embury SH.
Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation.
Blood.
1998;92:3445-3454 47. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998;101:877-889[Medline] [Order article via Infotrieve].
48.
Patel N, Brinkman-Van der Linden EC, Altmann SW, et al.
OB-BP1/Siglec-6: a leptin- and sialic acid-binding protein of the immunoglobulin superfamily [published erratum appears in J Biol Chem 1999 Sept 24;274(39):28058].
J Biol Chem.
1999;274:22729-22738
49.
Angata T, Varki A.
Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily.
Glycobiology.
2000;10:431-438
50.
Rosen SD, Singer MS, Yednock TA, Stoolman LM.
Involvement of sialic acid on endothelial cells in organ-specific lymphocyte recirculation.
Science.
1985;228:1005-1007 51. Issitt PD. Applied Blood Group Serology. Miami, FL: Montgomery Scientific Publications; 1985:50. 52. Conover WJ. Practical Nonparametric Statistics. New York: John Wiley & Sons; 1980:1.
53.
Beckstead JH, Stenberg PE, McEver RP, Shuman MA, Bainton DF.
Immunohistochemical localization of membrane
54.
Manodori AB, Barabino GA, Lubin BH, Kuypers FA.
Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin.
Blood.
2000;95:1293-1300
55.
Ho M, Schollaardt T, Niu X, Looareesuwan S, Patel KD, Kubes P.
Characterization of Plasmodium falciparum-infected erythrocyte and P-selectin interaction under flow conditions.
Blood.
1998;91:4803-4809
56.
Yipp BG, Anand S, Schollaardt T, Patel KD, Looareesuwan S, Ho M.
Synergism of multiple adhesion molecules in mediating cytoadherence of Plasmodium falciparum-infected erythrocytes to microvascular endothelial cells under flow.
Blood.
2000;96:2292-2298 57. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129:507-516[CrossRef][Medline] [Order article via Infotrieve].
58.
Hofstra TC, Kalra VK, Meiselman HJ, Coates TD.
Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst.
Blood.
1996;87:4440-4447
59.
Fadion E, Vordermeier S, Pearson TC, et al.
Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64.
Blood.
1998;91:266-274 60. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Sickle cell interactions with adherent leukocytes can initiate venular occlusion in sickle cell mice [abstract]. Blood. 2000;96(suppl 1):528A. 61. Olson PS, Ljungqvist U, Bergentz SE. Analysis of platelet, red cell and fibrin content in experimental arterial and venous thrombi. Thromb Res. 1974;5:1-19[CrossRef][Medline] [Order article via Infotrieve].
62.
Sevitt S.
The structure and growth of valve-pocket thrombi in femoral veins.
J Clin Pathol.
1974;27:517-28
63.
Bunn HF.
Pathogenesis and treatment of sickle cell disease.
N Engl J Med.
1997;337:762-769 64. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859-873[CrossRef][Medline] [Order article via Infotrieve].
65.
Chen S, Springer TA.
An automatic braking system that stabilizes leukocyte rolling by an increase in selectin bond number with shear.
J Cell Biol.
1999;144:185-200 66. van der Merwe PA. Leukocyte adhesion: high-speed cells with ABS. Curr Biol. 1999;9:R419-R22[CrossRef][Medline] [Order article via Infotrieve].
67.
Paszty C, Brion CM, Manci E, et al.
Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease.
Science.
1997;278:876-878 68. Embury SH, Mohandas N, Paszty C, Cooper P, Cheung ATW. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J Clin Invest. 1999;103:915-920[Medline] [Order article via Infotrieve]. 69. Roberts DD, Ginsburg V. Sulfated glycolipids and cell adhesion. Arch Biochem Biophys. 1988;267:405-415[CrossRef][Medline] [Order article via Infotrieve]. 70. Aruffo A, Kolanus W, Walz G, Fredman P, Seed B. CD62/P-selection recognition of myeloid and tumor cell sulfatides. Cell. 1991;67:35-44[CrossRef][Medline] [Order article via Infotrieve]. 71. Serra MV, Mannu F, Matera A, Turrini F, Arese P. Enhanced IgG- and complement-independent phagocytosis of sulfatide-enriched human erythrocytes by human monocytes. FEBS Lett. 1992;311:67-70[CrossRef][Medline] [Order article via Infotrieve].
72.
Needham LK, Schnaar RL.
The HNK-1 reactive sulfoglucuronyl glycolipids are ligands for L-selectin and P-selectin but not E-selectin.
Proc Natl Acad Sci U S A.
1993;90:1359-1363
73.
Roberts DD, Rao CN, Liotta LA, Gralnick HR, Ginsburg V.
Comparison of the specificities of laminin, thrombospondin, and von Willebrand factor for binding to sulfated glycolipids.
J Biol Chem.
1986;261:6872-6877
74.
Hillery CA, Du MC, Montgomery RR, Scott JP.
Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin.
Blood.
1996;87:4879-4886 75. Somers WS, Tang J, Shaw GD, Camphausen RT. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell. 2000;103:467-79[CrossRef][Medline] [Order article via Infotrieve]. 76. Henry S, Oriol R, Samuelsson B. Lewis histo-blood group system and associated secretory phenotypes. Vox Sang. 1995;69:166-182[Medline] [Order article via Infotrieve]. 77. Parsons SF, Spring FA, Chasis JA, Anstee DJ. Erythroid cell adhesion molecules Lutheran and LW in health and disease. Baillieres Best Pract Res Clin Haematol. 1999;12:729-45[Medline] [Order article via Infotrieve].
78.
Southcott MJ, Tanner MJ, Anstee DJ.
The expression of human blood group antigens during erythropoiesis in a cell culture system.
Blood.
1999;93:4425-435 79. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM. Development of potent thrombin receptor antagonist peptides. J Med Chem. 1996;39:4879-4887[CrossRef][Medline] [Order article via Infotrieve]. 80. Lowe JB, Ward PA. Therapeutic inhibition of carbohydrate-protein interactions in vivo. J Clin Invest. 1997;99:822-826[Medline] [Order article via Infotrieve].
81.
Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP.
Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation.
Blood.
1993;82:3253-3258 82. Gupta K, Gupta P, Solovey A, Hebbel RP. Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochim Biophys Acta. 1999;1453:63-73[Medline] [Order article via Infotrieve]. 83. Chaplin H Jr, Monroe MC, Malecek AC, Morgan LK, Michael J, Murphy WA. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J. 1989;66:574-584[Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  G. J. Kato and M. T. Gladwin Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy JAMA, December 10, 2008; 300(22): 2638 - 2646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Y. Setty and S. G. Betal Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes Blood, January 15, 2008; 111(2): 905 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Kim, V. Rajagopal, C. Gonsalves, C. Johnson, and V. K. Kalra A Novel Role of Hypoxia-Inducible Factor in Cobalt Chloride- and Hypoxia-Mediated Expression of IL-8 Chemokine in Human Endothelial Cells J. Immunol., November 15, 2006; 177(10): 7211 - 7224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Kaul, X.-d. Liu, X. Zhang, L. Ma, C. J. C. Hsia, and R. L. Nagel Inhibition of sickle red cell adhesion and vasoocclusion in the microcirculation by antioxidants Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H167 - H175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Nolan, D. F. Wyszynski, L. A. Farrer, and M. H. Steinberg Hemolysis-associated priapism in sickle cell disease Blood, November 1, 2005; 106(9): 3264 - 3267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Morris, G. J. Kato, M. Poljakovic, X. Wang, W. C. Blackwelder, V. Sachdev, S. L. Hazen, E. P. Vichinsky, S. M. Morris Jr, and M. T. Gladwin Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease JAMA, July 6, 2005; 294(1): 81 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Belcher, H. Mahaseth, T. E. Welch, A. E. Vilback, K. M. Sonbol, V. S. Kalambur, P. R. Bowlin, J. C. Bischof, R. P. Hebbel, and G. M. Vercellotti Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2715 - H2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Embury, N. M. Matsui, S. Ramanujam, T. N. Mayadas, C. T. Noguchi, B. A. Diwan, N. Mohandas, and A. T. W. Cheung The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo Blood, November 15, 2004; 104(10): 3378 - 3385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Matsui, A. Varki, and S. H. Embury Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin Blood, November 15, 2002; 100(10): 3790 - 3796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Goel and S. L. Diamond Adhesion of normal erythrocytes at depressed venous shear rates to activated neutrophils, activated platelets, and fibrin polymerized from plasma Blood, November 15, 2002; 100(10): 3797 - 3803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Turhan, L. A. Weiss, N. Mohandas, B. S. Coller, and P. S. Frenette Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm PNAS, March 5, 2002; 99(5): 3047 - 3051. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
4
,
) or
absence (
) of mAb 9E1. The data are mean percent adherence from 12 replicate experiments. Significant inhibition of adherence due to mAb
9E1 with P < .05 is denoted by *. (B) Titration of
adhesion inhibition by mAb 9E1. The data from this experiment are mean
percent adherence plotted versus the dilution of mAb 9E1. 
, AA,
thrombin; 
, AA, +thrombin; 
, SS, 
) or sLeX
(
) tetrasaccharide is shown. 
). The
100% adherence is the mean number of untreated nonsickcle (AA)
RBCs/field in a well in which BSA was immobilized. SS, sickle
erythrocytes. The data are mean percent adherence for 4 nonsickle and 6 sickle RBC samples. Differences in adherence with P < .05
were determined to be significant. Significant adhesion is compared to
adhesion to BSA (*) and to Siglec (§), and significant inhibition of
adhesion to P-selectin due to EDTA is denoted by
.
,
P-seclectin, untreated;
,
P-selectin, sialidase. The data are mean percent adherence for 3 nonsickle and 5 sickle RBC samples. Significant adhesion
(P < .05) is compared to adhesion to Siglec-6 (§) and
significant inhibition of adhesion to P-selectin due to sialidase is
denoted by